Coagulation Tests Explained: PT, INR, APTT, and D-Dimer

Coagulation tests — also called clotting tests or coagulation studies — are blood tests that assess the body’s ability to form clots and stop bleeding. They measure the function of the coagulation cascade: a series of reactions involving clotting proteins (factors) that work together to produce a stable blood clot at the site of vessel injury. These tests are used to investigate unexplained bleeding or bruising, screen for inherited clotting disorders, monitor anticoagulant therapy, and assess clotting function before surgery.

The Coagulation Cascade

When a blood vessel is damaged, the coagulation cascade is activated via two pathways that converge on a common final pathway. The extrinsic pathway is triggered by tissue factor (released by damaged tissue) and involves factor VII. The intrinsic pathway is triggered by contact with exposed collagen or damaged endothelium and involves factors XII, XI, IX, and VIII. Both pathways activate factor X, which leads (with factor V) to conversion of prothrombin to thrombin. Thrombin then converts fibrinogen to fibrin, which cross-links to form a stable clot. Each coagulation test is designed to assess one or more of these pathways.

PT and INR (Prothrombin Time / International Normalised Ratio)

The prothrombin time (PT) measures how long it takes for plasma to clot when tissue factor and calcium are added — activating the extrinsic pathway. It reflects the function of factors VII, X, V, II (prothrombin), and I (fibrinogen). Normal PT is approximately 11–13 seconds. A prolonged PT indicates deficiency or dysfunction in one or more of these factors, which can occur in vitamin K deficiency (warfarin works by blocking vitamin K-dependent factors II, VII, IX, and X), liver disease (which impairs clotting factor production), disseminated intravascular coagulation (DIC), or inherited deficiency of factors in this pathway. The INR is calculated by normalising the patient’s PT ratio against an international standard reagent, allowing results to be compared across different laboratories. INR is the standard way of monitoring warfarin therapy: a target INR of 2.0–3.0 is used for most indications (e.g., atrial fibrillation, DVT/PE prevention); a target of 2.5–3.5 is used for mechanical heart valves.

APTT (Activated Partial Thromboplastin Time)

The APTT (also written aPTT) measures clotting time when the intrinsic pathway is activated by contact activator and calcium. It reflects the function of factors XII, XI, IX, VIII, X, V, II, and I. Normal APTT is approximately 25–35 seconds (varies by laboratory). A prolonged APTT suggests deficiency in one or more intrinsic or common pathway factors, including haemophilia A (factor VIII deficiency) or haemophilia B (factor IX deficiency), von Willebrand disease (which reduces factor VIII), unfractionated heparin therapy (heparin acts on thrombin and factor Xa via antithrombin), lupus anticoagulant (an antiphospholipid antibody that prolongs APTT in vitro but is associated with increased clotting risk in vivo), or liver disease. APTT is used to monitor unfractionated heparin infusions and to investigate abnormal bleeding.

Fibrinogen

Fibrinogen (factor I) is the soluble plasma protein that is converted to insoluble fibrin by thrombin to form the structural scaffold of a blood clot. Measuring fibrinogen is important in patients with suspected DIC, severe liver disease, major haemorrhage, or before surgery in high-risk patients. Typical reference range: 1.5–4.5 g/L. Low fibrinogen (hypofibrinogenaemia) occurs in DIC (where fibrinogen is consumed as clots form throughout the circulation), liver failure (reduced synthesis), inherited afibrinogenaemia or hypofibrinogenaemia, or following large-volume blood transfusion or haemorrhage. Fibrinogen is also an acute phase reactant — it rises in inflammation, infection, and pregnancy, which can mask underlying deficiency.

D-Dimer

D-dimer is a small protein fragment produced when fibrin clots are broken down by plasmin (the body’s clot-dissolving enzyme). An elevated D-dimer indicates that clot formation and fibrinolysis are occurring. D-dimer is primarily used as a rule-out test for venous thromboembolism (VTE) — deep vein thrombosis (DVT) and pulmonary embolism (PE). A normal D-dimer in a patient with low or moderate pre-test probability of DVT or PE makes these diagnoses very unlikely and can avoid the need for imaging. However, D-dimer has very low specificity: it is elevated in many conditions including pregnancy, post-surgery, infection, cancer, trauma, atrial fibrillation, and simply with older age. A raised D-dimer does not confirm DVT or PE — imaging (ultrasound for DVT, CT pulmonary angiography for PE) is required for diagnosis. D-dimer is also elevated in DIC, where widespread intravascular clotting and fibrinolysis occur simultaneously.

Mixing Studies and Factor Assays

When PT or APTT is prolonged, mixing studies help distinguish between factor deficiency and inhibitor (antibody) presence. Patient plasma is mixed 1:1 with normal plasma: if the prolonged time corrects, it suggests factor deficiency (the normal plasma supplies the missing factor); if it does not correct, it suggests an inhibitor. Specific factor assays measure the activity of individual clotting factors (expressed as a percentage of normal activity) and are used to diagnose and classify haemophilia, monitor factor replacement therapy, and investigate other specific clotting disorders.

References

1. National Library of Medicine. Coagulation tests. MedlinePlus. https://medlineplus.gov/lab-tests/
2. NHS. Blood clotting tests. https://www.nhs.uk/conditions/blood-clotting-tests/
3. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845–854.
4. Kearon C et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest. 2016;149(2):315–352.
5. NICE Guideline NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. 2020.